Avance Clinical to Showcase its Early Phase Center of Excellence Model at AusBiotech International 2026
Visit Avance Clinical at Stand #72, AusBiotech International Conference 2026, 21–23 October at the Gold Coast Convention and Exhibition Centre.
Search results
We found 173 results for: “phase ii”
Avance Clinical at Seoul Global Forum 2026 | Early-Phase CRO
Avance Clinical and the Department of Food & Medical Products Regulatory Policy meet Korean biotechs at Seoul Global Forum 2026 on November 17 to discuss early-phase trials in Australia.
Avance Clinical at BIO CHINA 2027 | Early-Phase CRO
Avance Clinical, the global CRO for biotechs, attends BIO CHINA 2027 (March 10–12, Suzhou) to discuss a global development pathway. Book a meeting.
Rethinking risk-based monitoring in early phase clinical trials
Discover how risk-based monitoring strategies like tSDV can improve early phase trial oversight without compromising data integrity.
Avance Clinical at BIO-Europe 2026 | Early-Phase CRO
Avance Clinical, Australia's early-phase CRO, exhibits at BIO-Europe 2026, Booth #8-24. FDA/EMA-accepted data and fast study start-up. Book a meeting.
AusBiotech International Conference 2026 | Early-Phase CRO for Biotechs
Avance Clinical is exhibiting at AusBiotech International Conference 2026 on the Gold Coast.
Why Avance Clinical for Early Phase Clinical Trials in Australia
Biotechs choose Avance Clinical when they need more than access to Australia – they need a CRO partner that can turn the Australian framework into a faster, more predictable early phase program.
Avance Clinical’s Oncology Center of Excellence is Re-shaping Early Phase Cancer Research
Avance Clinical Appoints Liahna Toy to Lead Global Early Phase Center of Excellence
Avance Clinical, a global full-service CRO headquartered in Australia dedicated to servicing biotech, announces the appointment of Liahna Toy as Senior Vice President & Head of Early Phase Center of Excellence, reinforcing the company’s strategic focus on accelerating high-quality early-phase trials for emerging biotech sponsors.
The Phase 2 Endpoint Dilemma: Bridging Subjective Scales and Objective Measures in Neurodegenerative Trials
Phase 2 neurodegenerative trials are increasingly challenged by slow disease trajectories, heterogeneous patient populations, and blunt legacy endpoints that struggle to detect treatment-related change over typical study durations.